Lung cancer combo shows promise but study ends early
NCT ID NCT04549428
First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tested whether adding a single dose of radiation to the immunotherapy drug atezolizumab could help people with advanced lung cancer whose disease had worsened after chemotherapy and another immunotherapy. The trial planned to enroll 12 adults with stage IV non-small cell lung cancer. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cantonal Hospital of Graubünden (KSGR)
Chur, 7000, Switzerland
-
Geneva University Hospitals (HUG)
Geneva, 1205, Switzerland
-
Oncology Institute of Southern Switzerland
Bellinzona, 6500, Switzerland
Conditions
Explore the condition pages connected to this study.